Leriglitazone meets primary endpoint in pivotal cALD trial
12th December 2024 Uncategorised 0
Promising trial results support marketing authorisation application

More: Leriglitazone meets primary endpoint in pivotal cALD trial
Source: News
Promising trial results support marketing authorisation application

More: Leriglitazone meets primary endpoint in pivotal cALD trial
Source: News
© 1994 - 2026 B.M. Pharmaceuticals